Astria Therapeutics/ATXS

$11.00

1.76%
-
1D1W1MYTD1YMAX

About Astria Therapeutics

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Ticker

ATXS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jill Milne

Employees

59

Headquarters

Boston, United States

ATXS Metrics

BasicAdvanced
$593.5M
Market cap
-
P/E ratio
-$2.34
EPS
0.76
Beta
-
Dividend rate
$593.5M
0.75563
$16.90
$4.26
1.02M
21.727
-30.04%
-53.48%
-31.37%
3.001
2.441
35.37%

What the Analysts think about ATXS

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
123.36% upside
High $33.00
Low $18.00
$11.00
Current price
$24.57
Average price target

ATXS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-31.4M
77.4%
Profit margin
0%
-

ATXS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20.49%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.40
-$0.45
-$0.63
-$0.94
-
Expected
-$0.55
-$0.49
-$0.49
-$0.78
-$0.36
Surprise
-27.51%
-7.63%
29.63%
20.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Astria Therapeutics stock?

Astria Therapeutics (ATXS) has a market cap of $593.5M as of April 15, 2024.

What is the P/E ratio for Astria Therapeutics stock?

The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of April 15, 2024.

Does Astria Therapeutics stock pay dividends?

No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Astria Therapeutics dividend payment date?

Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.

What is the beta indicator for Astria Therapeutics?

Astria Therapeutics (ATXS) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Astria Therapeutics stock price target?

The target price for Astria Therapeutics (ATXS) stock is $24.57, which is 123.36% above the current price of $11. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Astria Therapeutics stock

Buy or sell Astria Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing